Job Description SummaryThe Japan Program Clinical Head (JPCH) is responsible for clinical program activities for approval and post approval commitment for Re-examination in Japan. The JPCH is responsible for one or more clinical programs across indications,
Entity: Customers & Products Job Family Group: Research & Technology Group Job Description: Job Purpose The Expert Technologist Technology Deployment provides technical expertise to the Japan markets, help plan their future technology requirements, deploy new technology,
General Information Job Advert Title: 創薬物性評価サイエンティスト Location: Tsukuba, Ibaraki Division: Product Research & Development Employment Class: Permanent Description 【About Astellas】 Astellas is a global life sciences company committed to turning innovative science into VALUE for patients.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
General Information Job Advert Title: 【つくば】分析開発サイエンティスト・外部製造技術統括（SME） Location: Tokodai, Ibaraki Division: External Manufacturing Employment Class: Permanent Description Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
The Opportunity QuidelOrtho unites the strengths of Quidel Corporation and Ortho Clinical Diagnostics, creating a world-leading in vitro diagnostics company with award-winning expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine. We are more
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Challenge Yourself and Impact the Future! Element Solutions Inc (NYSE:ESI) is a leading specialty chemicals company whose operating businesses formulate a broad range of solutions that enhance the performance of products people use every day. Developed
Job Description: Your responsibilities: Responsible for related academic communication which includes establishing and keeping the faithful relation with opinion leaders, academic cooperation with outside experts in the specialty area, i.e., urology, uro-oncology, and gastroenterology, sharing and
エア・リキードグループは、 フランス パリを本社とし、全世界78カ国に展開する産業と健康に技術とサービスで貢献するガス事業の世界的リーダーであり、創業100年以上の歴史を持つガス事業のグローバルにおけるパイオニアです。全世界64,500人の従業員。グループ全体売上は205億ユーロになります。 日本エア・リキードは1907年に創業。また日本エア・リキードの一員であるエア・リキード・オペレーション㈱は1999年、エア・リキード工業ガス㈱は2009年にそれぞれ創業し、その他関係会社とともに、日々の安全で効率的なオペレーションを通じ、欧米と日本独自の最先端テクノロジーを融合した革新的なイノベーションを世界中のパートナーへ提供しています。 事業拠点は世界78カ国、日本国内では27支店・営業所と事業拠点を広げ、「より安全に」 「より良い製品」 「より高い技術」 をポリシーとし、 常に安全を確保しながらお客様をサポートしています。エア・リキードグループの優れたチーム力とビジネスにおける多様性が堅実で持続的な成長・発展の基盤となっています。 また、グローバルネットワークを生かした海外勤務や国際交流の機会をはじめとして職種やキャリアパスに応じた各種教育プログラムなど人材開発、ダイバーシティー・インクルージョン（多様なバックグラウンド：性別、人種、国籍、宗教など）に力を注いでいます。お客さまから信頼されるパートナーとして、ともに成長できるよう可能性と幅広いチャンスを提供させていただきます。Since 1962, Air Liquide Advanced Technologies (ALAT) affiliates are recognized for their leading expertise in gas processing (gas treatment, separation, refrigeration, liquefaction, analysis and control, storage and
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Job Description SummaryAs a BML, you will define the biomarker strategies and plans for a set of programs/projects, defined by asset or by indication, from early to later stage clinical development. You will also build external